In EGFR Activating Mutations Osimertinib is Now The Standard of Care

In EGFR Activating Mutations Osimertinib is Now The Standard of Care

thoraciconcology

2 years
252 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Corey J. Langer, MD, FACP of the University of Pennsylvania discusses how in EGFR Activating Mutations, Osimertinib is now the Standard of Care. FDA is often behind clinical practice. In this case, the NCCN has already cited the important role of osimertinib based on the FLAURA trial, first sign treatment in all EGFR activating mutations. Since the end of 2017, osimertinib is now the standard of care in the front-line therapy of non-small-cell patients with activating EGFR mutation. What to use in the second line is a bit of a dilemma. This will be based increasingly on tissue and plasma testing when looking for mutations associated with acquired resistance. Its still an open field of inquiry and there is no standard. The default standard for this population when TKIs are no longer working is chemotherapy. Then, immunotherapy is for third or fourth line. In this case, the chemotherapy regimen is better in the salvage therapy on the EGFR mutated non-small-cell than immunotherapy.
Up Next Autoplay
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
ArcherDX Personalized Cancer Monitoring (PCM) Technology Designated by FDA as Breakthrough Device
Category: News
0 Views
Cancer-News 1 day
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Pacific Brain Tumor Center Recruiting Patients with Rare Cancer of the Skull and Spine for Groundbreaking Clinical Trial
Category: Brain Cancer
3 Views
Cancer-News 2 days
Molecular AI Product: What's Next For Research?
Molecular AI Product: What's Next For Research?
Category: News
10 Views
Cancer-News 1 week
Molecular AI Product: Can It Be Used Now or Later?
Molecular AI Product: Can It Be Used Now or Later?
Category: News
9 Views
Cancer-News 1 week
Caris Life Sciences Launches First Ever Molecular AI Product
Caris Life Sciences Launches First Ever Molecular AI Product
Category: News
24 Views
Cancer-News 1 week
Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors
Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors
Category: Other
19 Views
Cancer-News 1 week
Caris Life Sciences Launches First Ever Molecular AI Product: A Clinical Genomic Profiling Similarity Score
Caris Life Sciences Launches First Ever Molecular AI Product: A Clinical Genomic Profiling Similarity Score
Category: News
8 Views
Cancer-News 1 week
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
Category: News
6 Views
Cancer-News 1 week
New Study Finds Blood Clots More Likely in Children Who Receive Peripherally Inserted Central Catheters
New Study Finds Blood Clots More Likely in Children Who Receive Peripherally Inserted Central Catheters
Category: News
2 Views
Cancer-News 1 week
Role of Radiation in Kidney Cancer
Role of Radiation in Kidney Cancer
Category: Kidney Cancer
5 Views
kidneycancer 1 week